Recent acquisitions Acorda Therapeutics has recently sold assets to Merz Therapeutics. This could open up collaboration opportunities with Merz for future partnerships or sales agreements.

Product campaign launches Acorda has been actively launching campaigns and websites for its products, such as INBRIJA for Parkinson's. This indicates a focus on marketing efforts that could result in increased product visibility and potentially lead to sales growth.

Expansion in Latin America Acorda's submission to regulatory agencies in six Latin American countries for INBRIJA approval signals an expansion into new markets. This presents an opportunity for sales teams to explore partnerships and distribution channels in these regions.

Decrease in headcount Acorda has recently decreased its headcount through layoffs. This may indicate a need for operational efficiency and cost-saving measures, which could be leveraged by sales professionals offering solutions that streamline processes and reduce expenses.

Biotech industry trends Being in the biotech industry alongside similar companies like Alkermes and Neurocrine Biosciences, Acorda can leverage industry trends and competitive positioning to identify potential sales opportunities in areas where market demand and innovation align.